Playing CHESS

U.S. obesity play GI Dynamics plans $88.3M Australian IPO

Playing CHESS

U.S. obesity play GI Dynamics Inc. hopes to gain three years of runway in an Australian IPO to commercialize its EndoBarrier Gastrointestinal Liner to treat obesity and Type II diabetes.

EndoBarrier is intended to mimic the intestinal bypass portion of a surgical

Read the full 429 word article

How to gain access

Continue reading with a
two-week free trial.